Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 161

1.

Stool methylation-specific polymerase chain reaction assay for the detection of colorectal neoplasia in Korean patients.

Baek YH, Chang E, Kim YJ, Kim BK, Sohn JH, Park DI.

Dis Colon Rectum. 2009 Aug;52(8):1452-9; discussion 1459-63. doi: 10.1007/DCR.0b013e3181a79533.

PMID:
19617759
2.

[Human stool vimentin, oncostatin M receptor and tissue factor pathway inhibitor 2 gene methylation analysis for the detection of colorectal neoplasms].

Zhang JP, Wang J, Gui YL, Zhu QQ, Xu ZW, Li JS.

Zhonghua Yi Xue Za Zhi. 2011 Sep 20;91(35):2482-4. Chinese.

PMID:
22321844
3.

Novel methylation panel for the early detection of colorectal tumors in stool DNA.

Azuara D, Rodriguez-Moranta F, de Oca J, Soriano-Izquierdo A, Mora J, Guardiola J, Biondo S, Blanco I, Peinado MA, Moreno V, Esteller M, Capellá G.

Clin Colorectal Cancer. 2010 Jul;9(3):168-76. doi: 10.3816/CCC.2010.n.023.

PMID:
20643622
4.

Promoter methylation status of the MGMT, hMLH1, and CDKN2A/p16 genes in non-neoplastic mucosa of patients with and without colorectal adenomas.

Ye C, Shrubsole MJ, Cai Q, Ness R, Grady WM, Smalley W, Cai H, Washington K, Zheng W.

Oncol Rep. 2006 Aug;16(2):429-35.

PMID:
16820927
5.

Quantitative profiling of CpG island methylation in human stool for colorectal cancer detection.

Elliott GO, Johnson IT, Scarll J, Dainty J, Williams EA, Garg D, Coupe A, Bradburn DM, Mathers JC, Belshaw NJ.

Int J Colorectal Dis. 2013 Jan;28(1):35-42. doi: 10.1007/s00384-012-1532-5. Epub 2012 Jul 13.

PMID:
22791128
6.

Mutually exclusive promoter hypermethylation patterns of hMLH1 and O6-methylguanine DNA methyltransferase in colorectal cancer.

Fox EJ, Leahy DT, Geraghty R, Mulcahy HE, Fennelly D, Hyland JM, O'Donoghue DP, Sheahan K.

J Mol Diagn. 2006 Feb;8(1):68-75.

7.

Analysis of promoter methylation in stool: a novel method for the detection of colorectal cancer.

Lenhard K, Bommer GT, Asutay S, Schauer R, Brabletz T, Göke B, Lamerz R, Kolligs FT.

Clin Gastroenterol Hepatol. 2005 Feb;3(2):142-9.

PMID:
15704048
8.

MGMT promoter methylation and field defect in sporadic colorectal cancer.

Shen L, Kondo Y, Rosner GL, Xiao L, Hernandez NS, Vilaythong J, Houlihan PS, Krouse RS, Prasad AR, Einspahr JG, Buckmeier J, Alberts DS, Hamilton SR, Issa JP.

J Natl Cancer Inst. 2005 Sep 21;97(18):1330-8.

PMID:
16174854
9.

DNA stool test for colorectal cancer: hypermethylation of the secreted frizzled-related protein-1 gene.

Zhang W, Bauer M, Croner RS, Pelz JO, Lodygin D, Hermeking H, Stürzl M, Hohenberger W, Matzel KE.

Dis Colon Rectum. 2007 Oct;50(10):1618-26; discussion 1626-7.

PMID:
17762966
10.

[Gene methylation in stool for the screening of colorectal cancer and pre-malignant lesions].

Kang YP, Cao FA, Chang WJ, Lou Z, Wang H, Wu LL, Fu CG, Cao GW.

Zhonghua Wei Chang Wai Ke Za Zhi. 2011 Jan;14(1):52-6. Chinese.

PMID:
21271382
11.

Aberrantly methylated CDKN2A, MGMT, and MLH1 in colon polyps and in fecal DNA from patients with colorectal polyps.

Petko Z, Ghiassi M, Shuber A, Gorham J, Smalley W, Washington MK, Schultenover S, Gautam S, Markowitz SD, Grady WM.

Clin Cancer Res. 2005 Feb 1;11(3):1203-9.

12.

Hypermethylation of SFRP2 as a potential marker for stool-based detection of colorectal cancer and precancerous lesions.

Huang Z, Li L, Wang J.

Dig Dis Sci. 2007 Sep;52(9):2287-91. Epub 2007 Apr 5.

PMID:
17410438
13.

MGMT and MLH1 promoter methylation versus APC, KRAS and BRAF gene mutations in colorectal cancer: indications for distinct pathways and sequence of events.

de Vogel S, Weijenberg MP, Herman JG, Wouters KA, de Goeij AF, van den Brandt PA, de Bruïne AP, van Engeland M.

Ann Oncol. 2009 Jul;20(7):1216-22. doi: 10.1093/annonc/mdn782. Epub 2009 Jan 22.

PMID:
19164452
14.

A novel method to capture methylated human DNA from stool: implications for colorectal cancer screening.

Zou H, Harrington J, Rego RL, Ahlquist DA.

Clin Chem. 2007 Sep;53(9):1646-51.

15.

Genetic variants of methyl metabolizing enzymes and epigenetic regulators: associations with promoter CpG island hypermethylation in colorectal cancer.

de Vogel S, Wouters KA, Gottschalk RW, van Schooten FJ, de Goeij AF, de Bruïne AP, Goldbohm RA, van den Brandt PA, Weijenberg MP, van Engeland M.

Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):3086-96. doi: 10.1158/1055-9965.EPI-09-0289. Epub 2009 Oct 20.

16.

Quantitative detection of promoter hypermethylation in multiple genes in the serum of patients with colorectal cancer.

Leung WK, To KF, Man EP, Chan MW, Bai AH, Hui AJ, Chan FK, Sung JJ.

Am J Gastroenterol. 2005 Oct;100(10):2274-9.

PMID:
16181380
17.

Detection of hypermethylated fibrillin-1 in the stool samples of colorectal cancer patients.

Guo Q, Song Y, Zhang H, Wu X, Xia P, Dang C.

Med Oncol. 2013 Dec;30(4):695. doi: 10.1007/s12032-013-0695-4. Epub 2013 Aug 21.

PMID:
23963856
18.

Highly methylated genes in colorectal neoplasia: implications for screening.

Zou H, Harrington JJ, Shire AM, Rego RL, Wang L, Campbell ME, Oberg AL, Ahlquist DA.

Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2686-96.

19.

Microsatellite instability in aberrant crypt foci from patients without concurrent colon cancer.

Greenspan EJ, Cyr JL, Pleau DC, Levine J, Rajan TV, Rosenberg DW, Heinen CD.

Carcinogenesis. 2007 Apr;28(4):769-76. Epub 2006 Nov 4.

PMID:
17088260
20.

DNA methylation of phosphatase and actin regulator 3 detects colorectal cancer in stool and complements FIT.

Bosch LJ, Oort FA, Neerincx M, Khalid-de Bakker CA, Terhaar sive Droste JS, Melotte V, Jonkers DM, Masclee AA, Mongera S, Grooteclaes M, Louwagie J, van Criekinge W, Coupé VM, Mulder CJ, van Engeland M, Carvalho B, Meijer GA.

Cancer Prev Res (Phila). 2012 Mar;5(3):464-72. doi: 10.1158/1940-6207.CAPR-11-0315. Epub 2011 Dec 1.

Supplemental Content

Support Center